A system for determining maximum tolerated dose in clinical trial (Q5880093): Difference between revisions

@@ Property / MaRDI profile type @@
+MaRDI publication profile
@@ Property / MaRDI profile type: MaRDI publication profile / rank @@
+Normal rank
@@ Property / full work available at URL @@
+https://doi.org/10.1080/24754269.2021.1871708
+Normal rank
@@ Property / OpenAlex ID @@
+W3121830851
@@ Property / OpenAlex ID: W3121830851 / rank @@
+Normal rank
@@ Property / cites work @@
+Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
+Normal rank
@@ Property / cites work @@
+On the consistency of the continual reassessment method with multiple toxicity constraints
+Normal rank
@@ Property / cites work @@
+Semiparametric Dose Finding Methods
@@ Property / cites work: Semiparametric Dose Finding Methods / rank @@
+Normal rank
@@ Property / cites work @@
+Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer
+Normal rank
@@ Property / cites work @@
+Continual reassessment designs with early termination
+Normal rank
@@ Property / cites work @@
+Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
+Normal rank
@@ Property / cites work @@
+Miscellanea. A stopping rule for the continual reassessment method
+Normal rank
@@ Property / cites work @@
+Designs foe phase i cancer clinical trials with differentiation of graded toxicity
+Normal rank
@@ Property / cites work @@
+A phase I dose-finding study based on polychotomous toxicity responses
+Normal rank
@@ Property / cites work @@
+A study of the probit model with latent variables in Phase I clinical trials
+Normal rank
@@ Property / cites work @@
+The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
+Normal rank
@@ Property / cites work @@
+Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design
+Normal rank
@@ links / mardi / name / links / mardi / name @@
+Publication:5880093